Feature

Expanding the Therapeutic Landscape in Wet Age-related Macular Degeneration

The role of TKIs and sustained‑release delivery

  • By

  • February 19, 2026

  • 6 min

Share

Age-related macular degeneration (AMD) significantly impairs vision in individuals over 50, with education and intervention crucial for controlling its progression. Recent advancements in treatment highlight the shift from traditional anti-VEGF therapy to innovations like multi-target inhibitors and sustained-release drug delivery systems. These developments address the limitations of frequent injections and incomplete disease management by targeting various pathways involved in AMD, promising better long-term outcomes for patients.

Original Source(s)

Expanding the Therapeutic Landscape in Wet Age-related Macular Degeneration

The role of TKIs and sustained‑release delivery

  • February 19, 2026

  • 6 min

Related Content

Toward Better Management of Charles Bonnet Syndrome

Newly published guidance presents a practical guide to managing CBS in busy clinics

  • February 19, 2026

  • 3 min
Can Diabetic Eye Testing Be Simplified?

Three-test models matched nine-test battery in classifying disease stages

Patterns of Spread in Ocular Melanoma

Study examines lymphatic and distant metastasis risk